Have your say about the new PARP inhibitor - Niraparib (Zejula)
Governments are making decisions about access to the drug Niraparib (Zejula) for treatment of ovarian cancer - this is an opportunity for your voice to be heard by completing the following survey. This drug is not limited to people who have a BRCA mutation.
Ovarian Cancer Canada is seeking input from people living with ovarian cancer and their caregivers, who have had at least one recurrence of platinum-sensitive ovarian cancer and who may or may not have taken Niraparib.
As part of the pan Canadian Oncology Drug Review (pCODR) process, Ovarian Cancer Canada will provide a submission based on the experiences and opinions of patients and caregivers expressed through these surveys. pCODR is the national agency that makes funding recommendations to provinces on oncology drugs approved for sales in Canada. Your input is extremely important and, although there is no guarantee, may help to improve the availability and access to this drug for patients across Canada.
There are separate surveys for those
diagnosed with ovarian cancer and for caregivers.
Patients: https://www.surveymonkey.com/r/NiraparibSurvivor2019
Caregivers: https://www.surveymonkey.com/r/NiraparibCaregiverEN2019
Please forward these links to other interested parties, including caregivers.
For further information please contact Marilyn Sapsford at [email protected] or 1-877-413-7970 x231